Ultra 96+:Ultra-High-Throughput Antibody Production Services

Antibody production platform in 96 and 24 deep-well plates, resulting in a daily production throughput of ~1,000 antibodies at 100 -1,500 μg each, suitable for in vitro assays.

Protein Sciences: uHTP Antibody Production

WuXi Biologics’ Ultra 96+ uHTP antibody production platform can support AI drug development along with automated protein production integrated with expression, purification, and analytical modules. A daily production throughput of ~1,000 antibodies is performed in 96 and 24 deep-well plates (DWPs).

96/24 well DWP for 100-1,500 μg antibodies; Suitable for in vitro assays

Purification

QC

1-step Purification

A280, SEC-HPLC, Caliper

Automated protein production platform integrated with transfection, purification, and analytical modules

96 Well Plate

3 Weeks

Expression

TAT

Protein with one-step purification delivered within 3 weeks Expression scale is 1~3 mL using 96/24 deep-well plate Obtain 100~1,500 μg protein sufficient for in vitro studies

• Automated expression and purification • 3 mL culture; average yield ~0.5-1.0 mg/well • One-step Protein A purification

Ultra 96+ Service Details: Service Item

Gene synthesis, cloning and plasmid prep all included. Deliverables Duration

QC

96 x 0.8 mL CHO/HEK293 24 x 3 mL CHO/HEK293

100-800 μg

3 weeks

Titer, A280, Caliper (R/NR), and SEC-HPLC

0.5-2 mg

3 weeks

ariation in 96 DWP

The Average Titer and Recovery Rate of Ultra 96+ Platform The left histogram shows the average titer of mAb and Fc fusion protein production using the Ultra 96+ platform. High-titer production was accomplished with both types of antibodies in the 96 DWP at 1 mL culture volume. The graphs show an average recovery rate of 83% or more was achieved in both 1 mL culture using 96 DWP and 3 mL culture using 24 DWP. 1503

Recovery Rate (24 DWP)

Average 84%

90%

80%

70%

60%

50%

Titer Variation in 96 DWP

1 2 3 4 5 6 7 8 9 101112131415161718192021222324

Recovery Rate (24 DWP)

969

Average 84%

90%

1503

50% 50.0% 55.0% 60.0% 65.0% 70.0% 75.0% 80.0% 85.0% 90.0% 95.0% 1 3 5 7 9 11131517192123252729313335373941434547495153555759 Recovery Rate (96 DWP) Average 83% 60% 80% 1 2 3 4 5 6 7 8 9 101112131415161718192021222324 50.0% 55.0% 60.0% 65.0% 70.0% 75.0% 80.0% 85.0% 90.0% 95.0% 1 3 5 7 9 11131517192123252729313335373941434547495153555759 Recovery Rate (96 DWP) Average 83%

Need original image 70%

595

1013

969

mAb

Bispecific

Fc fusion

Control

mAb

Fc fusion

Case Study: WuXian TM uHTP Platform

The Ultra 96+ platform incorporates an ultra-high titer transient CHO expression system that significantly enhances titers and overall yields. In this case study, the Ultra 96+ platform showcases remarkable mean final yield of antibody drug molecules in 1 mL culture using 96-DWP, achieving 1.2 mg for 960 antibodies, 0.98 mg for 536 VHH-Fc, 0.55 mg for 557 Fab, and 0.3 mg for 100 His-VHH. The proteins are suitable for in vitro assays.

960 Antibodies

100 His-VHH

536 VHH-Fc

557 Flag-FABs

0 0.3 0.6 0.9 1.2 1.5 1.8 2.1

2

0.6

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9

0.5

1.5

0.55 mg

0.4

1.2 mg

0.98 mg

0.3 mg

1

0.3

0.2

0.5

0.1

0

0

96 Well DWP (1 mL/well)

Learn more: Protein Sciences: uHTP Antibody Production

About WuXi Biologics

WuXi Biologics is a leading contract research, development and manufacturing organization (CRDMO) that provides end-to-end capabilities to healthcare organizations worldwide. With operations in China, the United States, Ireland, Germany, and Singapore, we enable our partners to effectively and efficiently bring biologics and vaccines to patients worldwide through our comprehensive and high-quality drug development model.

The world’s leading global single-source platform from concept to commercialization.

wuxibiologics.com | info@wuxibiologics.com

5-9-2024

Page 1 Page 2

www.wuxibiologics.com

Powered by